STUDIES IN THYROID DISEASE

两种形式的辅助治疗旨在提高I-I的有效性- 131辐射治疗甲状腺癌的研究正在进行中。第一种是锂离子， 它用于延长I-131在癌症中的滞留时间。初步 以前的年度报告中已经描述了调查结果。第二个是 使用阿霉素(阿霉素)作为放射增敏剂。评估 其有效性，我们已经开始对高危甲状腺的随机研究 接受标准I-131治疗的癌症患者在接受或不接受 每次I-131前30分钟给予小剂量阿霉素(10 mg/m2) 治疗剂量。据我们所知，这是首次尝试随机化 使用I-131治疗甲状腺癌的患者。 其他I-131阴性但升高的全身扫描患者 甲状旁腺素治疗后血中甲状腺球蛋白浓度的变化 尝试通过治疗后扫描来定位癌症。大多数患者 已经发现治疗后扫描呈阳性，他们正在接受治疗 评估该疗法可能的有益效果。

Two forms of adjuvant therapy designed to improve the effectiveness of I- 131 radiation in thyroid cancer are under study. The first is lithium ion, which is used to prolong the retention of I-131 in the cancer. Preliminary findings have been described in previous annual reports. The second is the use of doxorubicin (adriamycin) as a radiosensitizing agent. To evaluate its effectiveness, we have begun to randomized study of high-risk thyroid cancer patients who receive standard I-131 therapy with or without the administration of low-dose adriamycin (10mg/m2) 30 min preceding each I-131 treatment dose. To our knowledge, this is the first attempt to randomize patients in a therapy protocol for thyroid cancer employing I-131. Other patients with negative I-131 whole body scans but elevated concentration of thyroglobulin in blood are given I-131 therapy in an attempt to localize the cancer by post-therapy scanning. Most patients have been found to have positive post-therapy scans and they are under evaluation for possible beneficial effects of the therapy.